drugset / Trial / NCT02195635

Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects

NCT02195635

Phase 1 Completed 24 enrolled Lexicon Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the effect of octreotide acetate injections (200 µg 3 times daily \[tid\]) on the pharmacokinetics (PK) of telotristat ethyl and its metabolite LP-778902 relative to administration of single-dose telotristat etiprate in healthy male and female subjects

Timeline

Start
2014-07
Primary completion
2014-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide 200 ug Subcutaneous
Subject Telotristat etiprate Unknown 500 mg Oral

Indications

No indication recorded.